Antibody-Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical's R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells.

The ADC BL-M07D1 is a HER2 specific antibody based on the drug Trastuzumab. Due to its HER2 binding, BL-M07D1 has anti-proliferative effects in a variety of HER2 driven solid tumors and secondarily, through a wt FC receptor, can mediate innate immune effector functions toward the cancer cells. Upon antibody mediated internalization, BL-M07D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induces genotoxic stress activating pathways leading to cancer cell death.

BL-M07D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of HER2+ solid tumor types.